This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bryan, S. A. Articles by Sabroe, I. Search for Related Content PubMed PubMed Citation Articles by Bryan, S. A. Articles by Sabroe, I.

Responses of Leukocytes to Chemokines in Whole Blood and Their Antagonism by Novel CC-Chemokine Receptor 3 Antagonists

National Heart and Lung Institute, and Leukocyte Biology Section, Biomedical Sciences Division, Faculty of Medicine, Imperial College School of Medicine, London, United Kingdom; and Inflammatory Diseases Unit, Roche Bioscience, Palo Alto, California

Correspondence and requests for reprints should be addressed to Ian Sabroe, MRC Clinician Scientist Fellow, University of Sheffield, Section of Functional Genomics, Division of Genomic Medicine, M Floor, Royal Hallamshire Hospital, Sheffield, S10 2JF. E-mail: i.sabroe{at}sheffield.ac.uk

CC-chemokine receptor 3 (CCR3)-stimulating chemokines are likely to have important in vivo roles in the regulation of eosinophil, basophil, and potentially helper T cell type 2 and mast cell recruitment. We have developed techniques to investigate the actions of eotaxin and other chemokines on multiple leukocyte populations in whole blood, without cell purification steps that might alter leukocyte responsiveness. We have shown that the potency of eotaxin in whole blood is limited by Duffy antigen binding, which may modulate the actions of this chemokine in vivo. We have also investigated the efficacy and potency of a new panel of small molecule antagonists of CCR3 on responses of eosinophils, neutrophils, basophils, and monocytes to chemokines, using whole blood assays of shape change, chemokine receptor internalization, and CD11b upregulation. These small molecule antagonists cause selective and potent inhibition of CCR3 on eosinophils and basophils, are bioavailable in blood, and are prototypic antagonists potentially of benefit in the treatment of human allergic disease. Such whole blood methods may also be employed in the investigation of other small molecule chemokine receptor antagonists.

Key Words: antagonist • basophil • chemokine • eosinophil

This article has been cited by other articles:

				H. Y. Sroussi, J. Berline, and J. M. Palefsky Oxidation of methionine 63 and 83 regulates the effect of S100A9 on the migration of neutrophils in vitro J. Leukoc. Biol., March 1, 2007; 81(3): 818 - 824. [Abstract] [Full Text] [PDF]

				T. Morokata, K. Suzuki, Y. Masunaga, K. Taguchi, K. Morihira, I. Sato, M. Fujii, S. Takizawa, Y. Torii, N. Yamamoto, et al. A Novel, Selective, and Orally Available Antagonist for CC Chemokine Receptor 3 J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 244 - 250. [Abstract] [Full Text] [PDF]

				R. M. Phillips, V. E. L. Stubbs, M. R. Henson, T. J. Williams, J. E. Pease, and I. Sabroe Variations in Eosinophil Chemokine Responses: An Investigation of CCR1 and CCR3 Function, Expression in Atopy, and Identification of a Functional CCR1 Promoter J. Immunol., June 15, 2003; 170(12): 6190 - 6201. [Abstract] [Full Text] [PDF]

				U. Warrior, E. M. Mckeegan, S. M. Rottinghaus, L. Garcia, L. Traphagen, G. Grayson, V. Komater, T. McNally, R. Helfrich, R. R. Harris, et al. Identification and Characterization of Novel Antagonists of the CCR3 Receptor J Biomol Screen, June 1, 2003; 8(3): 324 - 331. [Abstract] [PDF]

				M. J. Tobin Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332. [Full Text] [PDF]

				A. Menzies-Gow, S. Ying, I. Sabroe, V. L. Stubbs, D. Soler, T. J. Williams, and A. B. Kay Eotaxin (CCL11) and Eotaxin-2 (CCL24) Induce Recruitment of Eosinophils, Basophils, Neutrophils, and Macrophages As Well As Features of Early- and Late-Phase Allergic Reactions Following Cutaneous Injection in Human Atopic and Nonatopic Volunteers J. Immunol., September 1, 2002; 169(5): 2712 - 2718. [Abstract] [Full Text] [PDF]